These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 30828006)
1. Potential Use of Magnesium Oxide as an Excipient to Maintain the Hardness of Orally Disintegrating Tablets during Unpackaged Storage. Sakamoto T; Kachi S; Nakamura S; Yuasa H Chem Pharm Bull (Tokyo); 2019; 67(3):284-288. PubMed ID: 30828006 [TBL] [Abstract][Full Text] [Related]
2. Mechanism by Which Magnesium Oxide Suppresses Tablet Hardness Reduction during Storage. Sakamoto T; Kachi S; Nakamura S; Miki S; Kitajima H; Yuasa H Chem Pharm Bull (Tokyo); 2016; 64(9):1256-61. PubMed ID: 27581629 [TBL] [Abstract][Full Text] [Related]
3. Microwave-Assisted Development of Orally Disintegrating Tablets by Direct Compression. Kande KV; Kotak DJ; Degani MS; Kirsanov D; Legin A; Devarajan PV AAPS PharmSciTech; 2017 Aug; 18(6):2055-2066. PubMed ID: 27995465 [TBL] [Abstract][Full Text] [Related]
4. Tablet characteristics and pharmacokinetics of orally disintegrating tablets containing coenzyme Q10 granules prepared by different methods. Kashiwagura Y; Takusagawa S; Ikematsu Y; Tanaka S; Namiki N; Uchida S Acta Pharm; 2023 Mar; 73(1):107-119. PubMed ID: 36692467 [TBL] [Abstract][Full Text] [Related]
5. Formulation and Evaluation of Baclofen-Meloxicam Orally Disintegrating Tablets (ODTs) Using Co-Processed Excipients and Improvement of ODTs Performance Using Six Sigma Method. Abdelmonem R; Abdellatif MM; Al-Samadi IEI; El-Nabarawi MA Drug Des Devel Ther; 2021; 15():4383-4402. PubMed ID: 34690500 [TBL] [Abstract][Full Text] [Related]
6. Further improvement of orally disintegrating tablets using micronized ethylcellulose. Okuda Y; Irisawa Y; Okimoto K; Osawa T; Yamashita S Int J Pharm; 2012 Feb; 423(2):351-9. PubMed ID: 22138608 [TBL] [Abstract][Full Text] [Related]
7. [Influence of Storage Conditions after One-dose Packaging on Stability of Magnesium Oxide Tablets]. Sato K; Inaoka N; Kodama Y; Muro T; Nakamura T; Sasaki H; Kitahara T Yakugaku Zasshi; 2018; 138(11):1435-1441. PubMed ID: 30381651 [TBL] [Abstract][Full Text] [Related]
8. Maltodextrin: a novel excipient used in sugar-based orally disintegrating tablets and phase transition process. Elnaggar YS; El-Massik MA; Abdallah OY; Ebian AE AAPS PharmSciTech; 2010 Jun; 11(2):645-51. PubMed ID: 20405257 [TBL] [Abstract][Full Text] [Related]
9. Enalapril maleate orally disintegrating tablets: tableting and in vivo evaluation in hypertensive rats. Tawfeek HM; Faisal W; Soliman GM Pharm Dev Technol; 2018 Jun; 23(5):496-503. PubMed ID: 28489472 [TBL] [Abstract][Full Text] [Related]
10. Development of the Modified Ocimum gratissimum Seeds for Orally Disintegrating Tablets. Dang YNT; Tran PHL; Tran TTD Recent Pat Drug Deliv Formul; 2020; 14(1):40-47. PubMed ID: 31660821 [TBL] [Abstract][Full Text] [Related]
11. Investigation on the effect of polymer and starch on the tablet properties of lyophilized orally disintegrating tablet. Liew KB; Peh KK Arch Pharm Res; 2021 Aug; 44(8):1-10. PubMed ID: 25579848 [TBL] [Abstract][Full Text] [Related]
12. Impact of active ingredients on the swelling properties of orally disintegrating tablets prepared by microwave treatment. Sano S; Iwao Y; Kimura S; Noguchi S; Itai S Int J Pharm; 2014 Jul; 468(1-2):234-42. PubMed ID: 24709215 [TBL] [Abstract][Full Text] [Related]
13. Selection of generic preparations of famotidine orally disintegrating tablets for use in unit-dose packages. Yamazaki N; Iizuka R; Miyazawa S; Wada Y; Shimokawa K; Ishii F Drug Discov Ther; 2012 Oct; 6(5):263-8. PubMed ID: 23229147 [TBL] [Abstract][Full Text] [Related]
14. A new formulation for orally disintegrating tablets using a suspension spray-coating method. Okuda Y; Irisawa Y; Okimoto K; Osawa T; Yamashita S Int J Pharm; 2009 Dec; 382(1-2):80-7. PubMed ID: 19686825 [TBL] [Abstract][Full Text] [Related]
15. Formulation studies for mirtazapine orally disintegrating tablets. Yıldız S; Aytekin E; Yavuz B; Bozdağ Pehlivan S; Ünlü N Drug Dev Ind Pharm; 2016; 42(6):1008-17. PubMed ID: 26530146 [TBL] [Abstract][Full Text] [Related]
16. Orally Disintegrating Tablet Manufacture via Direct Powder Compression Using Cellulose Nanofiber as a Functional Additive. Nakamura S; Fukai T; Sakamoto T AAPS PharmSciTech; 2021 Dec; 23(1):37. PubMed ID: 34950985 [TBL] [Abstract][Full Text] [Related]
17. Formulation and evaluation of meloxicam oral disintegrating tablet with dissolution enhanced by combination of cyclodextrin and ion exchange resins. Samprasit W; Akkaramongkolporn P; Ngawhirunpat T; Rojanarata T; Opanasopit P Drug Dev Ind Pharm; 2015 Jun; 41(6):1006-16. PubMed ID: 24865111 [TBL] [Abstract][Full Text] [Related]
18. Formulation and evaluation of a montelukast sodium orally disintegrating tablet with a similar dissolution profile as the marketed product. Chen Y; Feng T; Li Y; Du B; Weng W Pharm Dev Technol; 2017 Mar; 22(2):168-172. PubMed ID: 26654222 [TBL] [Abstract][Full Text] [Related]
19. Development of Losartan Orally Disintegrating Tablets by Direct Compression: a Cost-Effective Approach to Improve Paediatric Patient's Compliance. Juan C; Gallo L; Gonzalez Vidal N AAPS PharmSciTech; 2024 Apr; 25(4):79. PubMed ID: 38589718 [TBL] [Abstract][Full Text] [Related]
20. Development and Optimization by Quality by Design Strategies of Frovatriptan Orally Disintegrating Tablets for Migraine Management. Mennini N; Orlandini S; Furlanetto S; Pasquini B; Mura P Curr Drug Deliv; 2018; 15(3):436-445. PubMed ID: 28595529 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]